Protagonist reports MIMRYLO FDA approval, Q3 2026 results, PN-881 Phase 2b planNov 5Quarterly updatePN-881Protagonist Therapeutics, Inc.
Protagonist posts Q2 2026 profit as ICOTYDE launch and rusfertide review advanceAug 5Quarterly updateicotrokinraJohnson & Johnson